3101 Broadway, Suite 650 Kansas City, MO 64111-2446 (816) 531-2177 (816) 531-4990 Fax http://www.accp.com

Barry L. Carter, Pharm.D., FCCP, BCPS College of Pharmacy University of Iowa Iowa City, IA 52242-1112 (319) 335-8779 (319) 353-5646 Fax

Past President:

Thomas C. Hardin, Pharm.D., FCCP, BCPS Ortho-McNeil Pharmaceutical, Inc. (210) 647-7398 (210) 682-4866 Fax

President Elect:

Bradley A. Boucher, Pharm.D., FCCP, BCPS University of Tennessee, Memphis (901) 448-4924 (901) 448-6064 Fax

Secretary:

J. Herbert Patterson, Pharm.D., FCCP, BCPS University of North Carolina at Chapel Hill (919) 962-0072 (919) 962-0644 Fax

Treasurer:

Marsha A. Baebel, Pharm D., FCCP, BCPS Kaiser Permanente of Colorado (303) 739-3556 (303) 739-3574 Fax

Regents:

Betty J. Dong, Pharm.D. University of California at San Francisco (415) 476-1972 (415) 476-6632 Fax

Julie A. Johnson, Pharm.D., FCCP, BCPS University of Florida (352) 392-3155 (352) 392-9388 Fax

Mary Lee, Pharm.D., FCCP, BCPS Midwestern University Chicago College of Pharmacy (630) 971-6417 (630) 971-6097 Fax

Michael Maddux, Pharm.D., FCCP St. Louis College of Pharmacy (314) 367-8700, x 1719 (314) 367-2784 Fax

Ralph H. Raasch, Pharm.D., FCCP, BCPS University of North Carolina at Chapel Hill (919) 962-0071 (919) 962-0644 Fax

David R. Rush, Pharm.D., BCPS Doctor of Pharmacy Consultants, Inc. (816) 373-4415 (816) 229-7749 Fax

Executive Director: Robert M. Elenbaas, Pharm.D., FCCP

Director, Education and Member Services: Peggy G. Kuehl, Pharm.D., FCCP, BCPS

Director, Publications: John D. Benz, B.S., M.B.A., BCPS

Director, Government and **Professional Affairs:** C. Edwin Webb, Pharm.D., MPH Washington, DC (202) 756-2227

(202) 756-4501 Fax

Editor, Pharmacotherapy: Richard T. Scheife, Pharm.D., FCCP Boston, MA (617) 636-5390 (617) 636-5318 Fax



April 18, 2001

Tien M.H. Ng, Pharm.D. University of Nebraska Medical Center Apartment #302 13908 Manderson Plaza Omaha, NE 68164-6208

Dear Dr. Ng:

On behalf of the ACCP Research Institute, it is my pleasure to inform you that you have been awarded the 2001 ACCP-Astra-Zeneca Cardiovascular Research Award for your proposal "Sympathetic Regulation of Cytokines in Heart Failure." You deserve special congratulations for preparing such a meritorious application.

All proposals were evaluated by two expert reviewers from the ACCP membership and by two members of the Grants and Fellowships Selection Committee (GFSC) using a standardized instrument. The review criteria were provided to you previously as part of our application instructions. All evaluations were returned to ACCP staff for summary and report to the GFSC. A member of the GFSC who was also one of the reviewers for each competition served as "primary reviewer." A conference telephone call, chaired by the primary reviewer, was held for each review panel, during which a consensus review of each proposal and recommendation regarding funding was developed. During the GFSC meeting, the primary reviewer summarized the panel's discussions and recommendations. Following discussion by the GFSC, a recipient was chosen for each Research Award. A summary evaluation for your proposal is enclosed with the anticipation that it will be of assistance in preparing future grant applications.

The ACCP-Astra-Zeneca Cardiovascular Research Award is considered a \$10,000 grant-in-aid in support of the conduct of your project, regardless of your proposal's stated budget. No provision is made for overhead funds. Payment will be made in June, 2001. Progress reports, using the form enclosed, will be requested every six months. Please complete and return the enclosed acknowledgment form so that we may send payment without delay in June.

Recognition of this year's Research Award recipients will occur during the Research Institute portion of our 2001 Annual Meeting, 11:30 a.m. - 11:45 a.m., Sunday, October 21 in Tampa, Florida. A photo session will immediately follow. We certainly hope that you will attend.

As a means to highlight the activities of the ACCP Research Institute, all Research Award recipients are requested to present the results of their study at the College's annual meeting. We thus look forward to your presentation at our 2002 Annual Meeting, October 20-23, in Albuquerque, New Mexico.

Finally, Harvey E. Maldow, R.Ph., M.S., serves as the Astra-Zeneca liaison to the ACCP Research Institute. As a way to help cement our relationship with A, I might suggest that you drop him a short thank you note. His address is: AstraZeneca LP, Director, Pharmacy Affairs, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437.

Again, congratulations.

Sincerely,

Robert M. Elenbaas, Pharm.D., FCCP

Director, Research Institute